We would love to hear your thoughts about our site and services, please take our survey here.
I certainly wouldn’t want to be out of this for a minute never mind an extended weekend!
No RNS but every other type of correspondence you could wish for to suggest everything is going according to plan.
Well overdue re-rate... next week?
Was very happy with the trading update, especially given current circumstances couldn’t have asked for much more.
Had anticipated us testing pre-covid levels of 52p...
Condolences to anyone who has sold a single share recently. It’s just a matter of time.
Sold Value £86.03k
Bought Value £622.89k
Ready to pop!
Okay... I have been following Avacta for a while although just opened a small position which I’ll be looking to add too. The potential here is exceptional.
Though I don’t quite understand the hate between companies. The market is large enough for all to succeed.
Not sure on the specific antibody discussion as it’s not particularly relevant here. However, if you’d like to learn about it the below links should help :).
https://www.thetimes.co.uk/article/coronavirus-immunity-breakthrough-is-a-shot-in-the-arm-for-everyone-dgws957r0
https://www.google.co.uk/amp/s/www.livescience.com/amp/antibodies-prevent-covid-19-reinfection-fishing-boat.html
I’m expecting another excellent week here alongside the similarly placed as the need for mass testing grows.
GLA
“ and the need for a vaccine diminishes.”
What planet are you on?
It’s clear the impetus is on mass testing (antibody & antigen) across the globe and will be for as far as I can see at the moment.
However, a vaccine is crucial, otherwise we’ll be living alongside this fatal virus forever.
I think gross margins are around $3 per test so looking at the upper end of the scale that’s approx $18,000,000 per annum. Excellent and well placed in a sector primed for growth.
Interesting that the food intolerance business is valued at almost twice the CD4.
This share does much better without the positive news flow. 15% drop since this morning. Laughable.
AVCT 40% up since news on mass testing.
This is positive news for the market as a whole as Omega will eventually be allocating their 5 covid tests to the 2,000,000+ manufacturing capacity.
The news today is also great, the CD4 testing industry is set to grow at CAGR 10.5% whilst being worth approx $4b by 2021. Achieving WHO prequalification speaks volumes.
The SP will catch up one day.
Agreed, not sure I’ll be able to get a yacht, but a rather fancy boat will suffice.
If I give my shares away at these silly prices I’ll be lucky to get a pedalo!
Anywhere else and this is 15/20%+ news.
But regardless of whether the SP wants to realise it. It’s excellent news for the company.
Those who sold sub 70p I Hope you are able to get back in because I think this is just a teaser, the calm before the storm if you like.
Charts are looking well for a breakout.
Patience is a virtue and is not easy to master.
The market needs sellers to allow those who have researched to be able to buy.
Good luck.
@1.90.
Thank you very much.
Interesting. 36% drop since yesterday’s highs.
Must be trying their best to relive some shares from the less sticky hands it would seem.
AVCT have done almost 30% since the news on mass antibody and antigen testing. Yet ODX haven’t moved.
Yet it’s clear we’ll have a large role to play with both, being involved with the RTC and Mologic. Omega Diagnostics name is even directly referenced on the government correspondence.
I feel something has got to give shortly. Whether it requires an RNS first? Most likely.
Great read. I thought I had enough shares but after reading that clearly not.
The strategy is testing at a mass scale. With the both antigen and antibody tests, where lab tests will be important alongside POC tests.
All tests which Omega are in the process of developing and have been for months.
“What could be contributed to the UK’s testing capacity now?
ELISA tests: 275,000 tests per week (increasing to 1 million+ by end of year)
Lateral flow production: 100,000 tests per week (increasing to 1 million+ by end of year)”.
This is going to be far bigger than I had actually anticipated.